Medical

In a note accompanying a set of articles on the impact of the FDA’s ban on the use of CFC propellants in metered dose inhalers and the transition to HFA inhalers, published online on May… Read more . . .

Adamis Pharmaceuticals has announced that a clinical study comparing its APC-2000 albuterol MDI with GSK’s Ventolin Evohaler MDI met its primary endpoint, showing equivalence in change from baseline of FEV1 for both doses tested (100… Read more . . .

Verona Pharma has announced what it calls “encouraging interim results” from a Phase 1/2 study of a new formulation of its RPL554 PDE3/4 inhibitor for the treatment of COPD exacerbations. The company had announced the… Read more . . .

A public/private partnership in Louisville, Kentucky called AIR Louisville will distribute 2,000 Propeller Health inhaler sensors to asthma patients across the city as part of a 2-year data collection program, according to Propeller. The FDA… Read more . . .

AstraZeneca has announced that data from two Phase 3 studies of its PT003 glycopyrronium/formoterol MDI for the treatment of COPD showed statistically significant improvements in lung function for patients using PT003 compared to each of… Read more . . .

Data to be presented at the upcoming annual meeting of The Endocrine Society show that healthy men treated with intranasal oxytocin consumed fewer calories and had reduced insulin sensitivity after use of the nasal spray.… Read more . . .

Adamis Pharmaceuticals has announced that data from a Phase 1 PK study its APC-5000 fluticasone/salmeterol DPI, a generic carrier-free version of Advair Diskus, show less systemic exposure to both components compared to Advair. The open-label… Read more . . .

A Phase 3 trial program of Sunovion Pharmaceutical’s SUN-101 glycopyrrolate inhalation solution for the treatment of moderate-to-very severe COPD has begun enrolling patients, the company announced. The program includes three studies expected to enroll about… Read more . . .

Boehringer Ingelheim has presented data from five Phase 3 trials of tiotropium Respimat for the treatment of asthma at the 2015 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting. The data come from… Read more . . .